The 120 kD product of the c-cbl oncogene is rapidly tyrosine phosphorylated and recruited to the EGF receptor following ligand binding. Cbl's oncogenic potential is activated by a large carboxy-terminal truncation that generated v-cbl and removes the Ring ®nger and proline-rich SH3-binding domains. Here we show that this truncation reveals a novel and highly conserved domain that can interact directly with the EGF receptor in a phosphorylation dependent manner. Furthermore we demonstrate that the v-cbl domain is not utilized by c-cbl for recruitment to the receptor since this binding property is not evident in c-cbl constructs with proline domain deletions, and it is only revealed following deletion of the Ring ®nger. We also analyse a loss-of-function mutation from the C. elegans homologue, sli-1, and show that the corresponding mutation in v-cbl ablates transformation and EGF receptor association. Thus our ®ndings provide further evidence that v-cbl possesses a novel and evolutionarily conserved phosphotyrosine binding domain and that the dual capability of EGF receptor binding by cbl involves two distinct mechanisms. In addition these ®ndings raise the possibility that v-cbl may transform by competing with c-cbl for phosphorylated binding sites on activated receptor complexes.
Introduction v-cbl is the transforming gene of the Cas NS-1 retrovirus which arose by recombination between the murine Cas-Br-M virus and c-cbl sequences . Cas NS-1 induces pre-B cell lymphomas and myelogenous leukemias in mice and acute transformation of immortalized rodent ®broblasts. The 40 kD protein encoded by v-cbl is markedly truncated compared with the cellular homologue, comprising the amino-terminal 38% of the c-cbl encoded protein (Blake et al., 1991) . The protein product of c-cbl is a 120 kD cytoplasmic protein and unlike v-cbl its overexpression is not associated with tumorigenesis (Blake et al., 1993) .
Gene bank searches have not revealed any known genes with signi®cant similarities to c-cbl, and as such the sequence has not provided de®nitive clues for a possible function. However analysis of the sequence reveals an abundance of positively charged residues in the amino-terminal v-cbl region, a Ring ®nger motif and a proline-rich domain of 200 amino acids which contains many Src homology (SH) 3 binding domains (Blake et al., 1991) . The recent ®nding that a 17 amino acid deletion at the amino-terminal end of the Ring ®nger will also activate cbl's oncogenic potential has provided important clues in studying cbl's role in tumorigenesis (Andoniou et al., 1994) . We found that this form of cbl, which was generated from a splice acceptor site mutation in the 70Z/3 pre-B cell lymphoma, has an enhanced susceptibility to be tyrosine phosphorylated compared to wild type p120 cbl (Andoniou et al., 1994; Bowtell and Langdon, 1995; Andoniou et al., 1996) . Thus deregulation of cbl tyrosine phosphorylation is associated with tumorigenesis.
Numerous studies have shown that p120 cbl is a ubiquitous substrate for protein tyrosine kinases. p120
cbl is phosphorylated in cells expressing the v-abl or bcr-abl tyrosine kinases and this mediates binding to the SH2 domain of the crkL adaptor protein (Andoniou et al., 1994; de Jong et al., 1995; Ribon et al., 1996) . Parallel studies have shown that p120 cbl is rapidly phosphorylated on tyrosine residues following activation of the T-cell antigen receptor, and that cbl is constitutively bound to the SH3 domains of the Grb2 adaptor protein (Donovan et al., 1994; Fukazawa et al., 1995; Buday et al., 1996) . Tyrosine phosphorylation of p120 cbl has also been observed following ligand-induced stimulation of the GM-CSF and erythroprotein receptors , the Fcg receptor (Marcilla et al., 1995) , the EGF receptor (Tanaka et al., 1996; Galisteo et al., 1995; Bowtell and Langdon, 1995; Solto and Cantley, 1996; Fukazawa et al., 1996) , the NGF, PDGF and FGF receptors (Galisteo et al., 1995) , the CSF-1 receptor (Tanaka et al., 1996; Wang et al., 1996) , the B-cell antigen receptor (Cory et al., 1995; Kim et al., 1995; Panchamoorthy et al., 1996) , the TPO/c-mpl receptor (Sasaki et al., 1995) and the CD38 receptor (Kontani et al., 1996) . These ®ndings indicate a pivotal role for cbl in tyrosine kinasemediated signal transduction.
Evidence that cbl plays an important role in regulating signals mediated by protein tyrosine kinases has also originated from genetic studies in the nematode Caenorhabditis elegans Yoon et al., 1995) . These studies identi®ed the cbl homologue in C. elegans by screening for suppressors of mutations of let-23, a receptor tyrosine kinase which is homologous to the mammalian EGF receptor. Let-23 signaling is essential for vulval induction in the nematode and mutations to let-23 will block this developmental pathway. Interestingly, mutations to a second locus termed sli-1 (suppressor of lineage defect) will fully restore vulval development in worms expressing reduction-of-function let-23 mutations . Thus genetic studies indicate sli-1 is a negative regulator of this developmental pathway which acts at or near the Let-23 receptor. Sequence analysis shows Sli-1 to be 43% homologous to mammalian c-cbl over its 582 amino acids, with greatest homology (55%) in the aminoterminal v-cbl region and the Ring ®nger domain (Yoon et al., 1995) . The ®nding that c-cbl is rapidly phosphorylated and recruited to the activated EGF receptor suggests that cbl may have a similar function in mammalian cells. To date two sli-1 mutations, sy143 and sy129, have been characterized that are strong suppressors of let-23 reduction-of-function mutations Yoon et al., 1995) . The sy143 mutation is located at amino acid 152, where a Gln is changed to a stop codon, and sy129 encodes a missense mutation that results in the substitution of Gly for Glu at amino acid 315 (Yoon et al., 1995) . Genetic analyses show that these two mutations are similar in severity to a de®ciency at the sli-1 locus . Thus the loss, or severe reduction, of sli-1 function that results from these mutations will restore signalling from a defective Let-23 receptor.
In this report we extend our study of cbl's involvement with the EGF receptor and provide evidence that c-cbl is capable of interacting with the EGF receptor via two distinct mechanisms. We show that the corresponding sli-1 mutation of Gly to Glu in v-cbl (i.e. G306E) results in the inability of v-cbl to transform ®broblasts and associate with the EGF receptor. This mutation in c-cbl also reduces the ability of p120 cbl to be tyrosine phosphorylated but unlike proline-domain deletions does not markedly aect recruitment to the receptor. Importantly this report demonstrates that the association between v-cbl and the EGFR is only revealed by the large carboxyterminal truncation that converts cbl to an oncogenic protein and that cbl and sli-1 proteins possess a novel and highly conserved EGF receptor binding domain.
Results

Recent studies show that p120
cbl is rapidly tyrosine phosphorylated and recruited to the EGF receptor following EGF stimulation (Bowtell and Langdon, 1995; Galisteo et al., 1995; Tanaka et al., 1996; Solto and Cantley, 1996; Fukazawa et al., 1996) . To further de®ne cbl's involvement in EGF receptor-mediated signalling, we examined a number of deletion and truncation mutants for their eect on cbl's ability to be tyrosine phosphorylated and to associate with the EGF receptor. These constructs remove 17 of the 22 tyrosine residues in c-cbl, 8 of which are conserved in sli-1 (Figure 1b) . Seven tyrosine residues are deleted in HUT-cbl, a truncated form of cbl isolated from the HUT 78 cutaneous T cell lymphoma line which has lost 257 C-terminal amino acids of c-cbl (Blake and Langdon, 1992) . The C-terminal deletion mutants encompass the proline-rich domain of c-cbl which contain many potential SH3-binding sites, including a PPVPPR motif (amino acids 494 ± 499) identical to that found in the Sos protein which is recognized by the Grb2 SH3 domain (Blake et al., 1991; Rozakis-Adcock et al., 1993; Li et al., 1993) . The D6Pro mutant deletes a sequence encoding six consecutive proline residues from amino acids 543 to 548. All mutants, with the exception of the most N-terminal deletion of amino acids 87 to 152 (D87/152), were stably expressed in NIH3T3 ®broblasts expressing the human EGF receptor (NhEGFR). Tyrosine residues which are not conserved in sli-1 are indicated with an asterisk (*). The D6Pro mutant deletes a sequence encoding six consecutive proline residues. Also shown are the positions of the v-cbl and HUT termination codons, the position of the G306E mutation and the 17 amino acid deletion found in 70Z/3 cbl. All constructs were HA-epitope tagged at the N-terminus EGF stimulation induces cbl tyrosine phosphorylation at multiple sites and this is not dependent on an intact proline-rich domain To determine which domains in cbl are important for EGF-induced tyrosine phosphorylation, lysates were prepared from EGF-stimulated NhEGFR ®broblasts expressing HA-tagged c-cbl and the various mutants shown in Figure 1b . Cbl proteins were immunoprecipitated with anti-HA antibodies and analysed by immunoblotting with anti-phosphotyrosine antibodies. Figure 1a shows that none of the deletions abolished cbl's ability to be tyrosine phosphorylated. Mutants D472/540, D543/645 and D6Pro which encompass the entire proline-rich domain were still phosphorylated at levels comparable to wild type c-cbl. Thus mutations within the proline-rich domain of cbl do not appreciably aect its ability to be tyrosine phosphorylated in response to EGF stimulation. These prolinedeletion mutants showed no detectable tyrosine phosphorylation in the absence of EGF stimulation (data not shown).
The D262/300, D302/350 and HUT-cbl mutants delete 3, 2 and 7 tyrosine residues respectively from c-cbl (Figure 1b ). Not surprisingly, these mutants showed a decrease in tyrosine phosphorylation, with HUT-cbl exhibiting the greatest reduction. This suggests that while one or more of the target tyrosine residues may have been deleted in these mutants, other sites exist outside of the regions deleted which are phosphorylated following EGF stimulation. Immunoblotting with anti-HA antibodies ( Figure 1a , lower panel) showed that the observed dierences in tyrosine phosphorylation were not due to dierences in the amounts of cbl protein immunoprecipitated. Similar results were obtained with these mutants expressed in Rat-1 ®broblasts stimulated through their endogenous EGF receptors (data not shown). These results indicate that EGF stimulation induces phosphorylation of cbl on multiple tyrosine residues and that this does not require an intact proline-rich domain.
The proline-rich domain of c-cbl mediates association with the EGF receptor Following EGF stimulation, a *170 kD phosphoprotein is seen to co-immunoprecipitate with cbl ( Figure  1a , lane 2, anti-phosphotyrosine blot). This protein has previously been shown to be the EGF receptor (EGFR) and it forms a rapid EGF-inducible complex with cbl (Tanaka et al., 1996; Galisteo et al., 1995; Bowtell and Langdon, 1995; . Figure 1a also shows the eect of the various deletion mutations on cbl's ability to associate with the EGFR.
Deletions within the proline-rich domain had a marked eect on cbl's ability to associate with the EGFR. Although the D472/540 mutant was expressed and tyrosine phosphorylated to a similar extent as wild type c-cbl the amount of EGFR detected in immunoprecipitates from cells expressing this mutant was greatly reduced (Figure 1a ). In cells expressing the D6Pro and D543/645 mutants, very little cbl association with the EGFR could be detected. In contrast however the D262/300, D302/350 and HUT-cbl mutants, which have their proline-rich domains intact, showed only partial reductions in the amount of co-immunoprecipitated EGFR (Figure 1a , antiphosphotyrosine blot).
These results demonstrate that the proline-rich domain of c-cbl is essential in mediating an association with the EGFR since deletions within this region greatly diminish the amount of EGFR that coimmunoprecipitates with cbl. The ability of the proline-deletion mutants to be eciently phosphorylated suggests that a strong association with the EGFR is not required for ecient cbl phosphorylation following EGF stimulation.
v-cbl binding to the EGFR is abolished by a loss-offunction mutation from sli-1
Genetic analyses of sli-1, the cbl homologue in C. elegans, implicate sli-1 as a negative regulator of Let-23 receptor-mediated signalling which acts at or near the Let-23 receptor, the homologue to the mammalian EGFR . Previously we showed that both c-cbl and the oncogenic v-cbl complex with the activated EGFR and that c-cbl is rapidly tyrosine phosphorylated following EGFstimulation (Bowtell and Langdon, 1995) . These results suggested that cbl may play a similar role as sli-1 in binding to and regulating the EGFR. sy129 is a loss-of-function sli-1 mutant isolated in a genetic screen by its ability to suppress the vulvaless phenotype associated with a Let-23 receptor mutant . The sy129 mutation results in a glycine to glutamic acid substitution at amino acid 315 in the sli-1 protein (Yoon et al., 1995) . This mutation corresponds to amino acid 306 in human ccbl and lies within a region of 80% (20/25) amino acid identity between cbl and sli-1 (Yoon et al., 1995) . We therefore introduced the corresponding loss-of-function sy129 sli-1 mutation into both c-cbl and v-cbl (i.e. G306E) to examine whether this mutation would perturb cbl's involvement with the EGFR. The position of the G306E mutation in c-cbl is indicated in Figure 1b .
Lysates were prepared from EGF-stimulated NhEGFR ®broblasts expressing HA-tagged c-cbl, G306E-c-cbl, v-cbl and G306E-v-cbl. Following immunoprecipitation with anti-HA antibodies, immune complexes were resolved by SDS ± PAGE, transferred to nitrocellulose membranes and analysed by immunoblotting with anti-phosphotyrosine and anti-HA antibodies. We found that the G306E mutation aected both c-cbl tyrosine phosphorylation and association with the EGFR. The G306E-c-cbl mutant exhibited reduced tyrosine phosphorylation relative to wild type c-cbl, even though both proteins were immunoprecipitated in similar amounts ( Figure 2a ). This decrease in tyrosine phosphorylation was also accompanied by a reduced ability of the G306E-c-cbl mutant to bind the EGFR, as evidenced by lower levels of the 170 kD phosphoprotein detected in G306E-c-cbl immunoprecipitates. However the ability of the G306E mutation to aect cbl's association with the EGFR was most marked by its eect in v-cbl. The v-cbl immunoprecipitate revealed an association with the phosphorylated receptor whereas no evidence of phosphorylated receptor could be detected in the G306E-v-cbl immunoprecipitates (Figure 2a ). Thus The anti-phosphotyrosine blot also showed that the G306E mutation abolished v-cbl binding to a *42 kD phosphoprotein (p42). Interestingly, p42 was not found to be associated with c-cbl in EGF-stimulated cells. This phosphoprotein does not represent phosphorylated v-cbl as the anti-HA blot shows that v-cbl migrates with a slightly faster mobility than p42. Stripping and reprobing the anti-phosphotyrosine blot with anti-HA antibodies also con®rmed that p42 is distinct from v-cbl (data not shown). The same results were observed upon serum stimulation of quiescent NIH3T3 ®broblasts (Figure 2b ) where we demonstrated an association between v-cbl and p42 and showed that this association was disrupted by the G306E mutation.
Cbl has been shown to associate with the 36 ± 42 kD crk proteins in activated T cells and in cells expressing activated abl kinases (de Jong et al., 1995; Ribon et al., 1996; Buday et al., 1996; Reedquist et al., 1996; Andoniou et al., 1996) . The p42/p44 MAP kinase proteins are also known to be tyrosine phosphorylated following EGF stimulation (Burgering et al., 1993; Li et al., 1994) . However immunoblotting total cell lysates from EGF-stimulated cells with anti-crkII, anti-crkL, or anti-MAP kinase antibodies showed that while these proteins are well expressed in ®broblasts, they do not migrate with the same mobility as the 42 kD phosphoprotein seen in v-cbl immunoprecipitates (data not shown). Thus the identity of the v-cbl associated p42 remains unknown.
v-cbl's association with the EGFR is dependent on receptor activation and deletion of the Ring ®nger domain v-cbl's oncogenic potential is only revealed by a carboxy truncation that extends beyond and deletes the Ring ®nger domain (Andoniou et al., 1994) . We have shown that large carboxy-terminal truncations that delete the proline-rich domain, but still retain the Ring ®nger, are unable to convert cbl to an oncogenic protein (Andoniou et al., 1994) . Although v-cbl shows no signi®cant sequence identity with known proteins it does represent a region that is highly conserved among all cbl homologues isolated to date (Blake et al., 1991; Keane et al., 1995; Yoon et al., 1995) . Thus v-cbl may encode a novel protein-binding domain which interacts with the EGFR through an uncharacterized mechanism. In a recent study we revealed v-cbl's association with the tyrosine phosphorylated EGFR (Bowtell and Langdon, 1995) , however it was not determined whether this binding is dependent on ligand-induced receptor activation.
Lysates from quiescent and EGF-stimulated NhEGFR ®broblasts expressing HA-tagged c-cbl, vcbl, G306E-v-cbl and a cbl construct encoding 480 amino-terminal residues of c-cbl were immunoprecipitated with anti-HA antibodies and immunoblotted with anti-phosphotyrosine, anti-EGFR and anti-HA antibodies ( Figure 3 ). As expected, the anti-phosphotyrosine blot detected a 170 kD phosphoprotein in c-cbl and v-cbl immunoprecipitates from EGF-stimulated cells (Figure 3, upper panel) . Immunoblotting with anti-EGFR antibodies con®rmed that the 170 kD phosphoprotein is the EGFR (Figure 3 , middle panel). The anti-EGFR immunoblot did not detect the presence of the EGFR in c-cbl and v-cbl immunoprecipitates from unstimulated cells indicating that both proteins are dependent on EGF to induce their association with the receptor. In contrast, no receptor association was detected in immunoprecipitates from cells expressing G306E-v-cbl and the 480-cbl truncation mutant. The 480-cbl mutant has an intact Ring ®nger but the proline-rich domain is totally deleted and this protein does not transform NIH3T3 ®broblasts (Andoniou et al., 1994) . These ®ndings con®rm the importance of the proline-rich domain in recruiting c-cbl to the EGFR and demonstrate that the amino-terminal EGFR-binding domain of c-cbl is only revealed when the carboxy-terminal truncation deletes the Ring ®nger. v-cbl binds directly to phosphorylated EGFR v-cbl is not detectably phosphorylated following EGF stimulation and its ability to associate with the EGFR in the absence of the proline domain makes it unlikely to be recruited to the receptor via an SH2 or SH3 domain-containing protein. This raised the possibility that v-cbl may encompass a phosphotyrosine binding (PTB) domain distinct from the previously characterized SH2 or PTB domains which would permit it to directly interact with the activated receptor. To test this, anti-EGFR immunoprecipitates from quiescent and EGF-stimulated cells were immobilized onto nitrocellulose membranes and probed with a GST-v-cbl fusion protein (Figure 4 ). Subsequent immunoblotting with anti-GST antibodies detected GST-v-cbl bound to the EGFR immunoprecipitated from EGF-stimulated but not quiescent cells (Figure 4a, lanes 1 and 2) . This interaction was speci®c for v-cbl as no binding was observed upon probing a duplicate membrane with the GST moiety alone (data not shown).
GST-v-cbl binding was no longer detected following carboxy-terminal truncation of the EGFR to 1028 or 963 amino acids (Figure 4a, lanes 3 and 4) . The 1028 EGFR mutant removes 4 of the 5 autophosphorylation sites in the C-terminal tail of the receptor (Downward et al., 1984; Walton et al., 1990) and accordingly, produces only a weak signal on an anti-phosphotyrosine blot. The remaining autophosphorylation site, Y992, is deleted in the 963 EGFR mutant which terminates immediately following the tyrosine kinase domain. As shown previously, this protein exhibits no detectable tyrosine phosphorylation (Walton et al., 1990) . These results indicate that the region bound by v-cbl resides between amino acids and 1028 and 1168 of the EGFR and that autophosphorylation of Y992 is not required for this interaction.
Ligand binding induces receptor dimerization and kinase activation and involves a number of conformational changes accompanied by a large increase in the level of EGFR tyrosine phosphorylation due to the presence of autophosphorylation sites located at the carboxy-terminus of the receptor (reviewed in van der Geer et al., 1994) . To distinguish whether v-cbl binding is dependent on receptor activation or the ensuing receptor phosphorylation, the EGFR was immunoprecipitated from quiescent and EGF-stimulated cells in the absence of the tyrosine phosphatase speci®c inhibitor, sodium orthovanadate (Na 3 VO 4 ) (Swarup et al., 1982) . Omission of Na 3 VO 4 greatly reduced the extent of EGFR phosphorylation as detected by antiphosphotyrosine immunoblotting and was also evident by the lack of a mobility shift in the EGFR immunoprecipitated from EGF-stimulated cells (Figure 4b ). Under these conditions, no binding could be detected when the membrane was probed with GST-vcbl. These results demonstrate that v-cbl forms a direct association with the carboxy-terminal region of the EGFR and this interaction is dependent on receptor phosphorylation.
Receptor dissociation from v-cbl but not c-cbl in SDS lysis buer
The experiments described above indicate that c-cbl and v-cbl utilize distinct binding mechanisms for recruitment to the EGF receptor. To examine the relative strengths of these interactions we compared c-cbl and v-cbl immunoprecipitates in Triton X-100 lysis buer with or without the addition of 0.1% SDS. Figure 5 shows anti-HA immunoprecipitates of EGF-stimulated NhEGFR cells expressing HA-c-cbl or HA-v-cbl followed by immunoblotting with anti-phosphotyrosine and anti-HA antibodies. As shown previously both c-cbl and v-cbl are associated with the activated EGFR when immunoprecipitated in TBS lysis buer containing 1% Triton X-100 ( Figure 5 , Blot anti-P-Tyr, SDS 7). The addition of 0.1% SDS to the lysis and wash buers did not alter the amount of receptor associated with c-cbl whereas the v-cbl receptor association was markedly reduced ( Figure 5 , Blot anti-P-Tyr, SDS +). This indicates that direct receptor binding by v-cbl is more readily dissociated than the SH2-SH3 interaction that recruits c-cbl to the receptor. The longer exposure of the anti-phosphotyrosine blot in Figure 5 reveals that the p42 association was not disrupted by SDS, nor was the doublet at *50 kD which presumably represents Shc (Pelicci et al., 1992; Bowtell and Langdon, 1995) . The longer exposure also shows the array of tyrosine phosphorylated proteins which are associated with c-cbl (either directly or indirectly), and that most of these associations are lost by the truncation to generate v-cbl. Indeed the only tyrosine phosphorylated proteins that are detectably associated with v-cbl are the EGFR, Shc and p42.
The G306E mutation ablates v-cbl transformation
The ability of the G315E substitution to relieve sli-1's negative regulation of the Let-23 receptor and the -c-cbl
I.P. : Anti-HA Blot : Anti-P-Tyr I.P. : Anti-HA Blot : Anti-HA SDS : Figure 5 Receptor dissociation from v-cbl but not c-cbl in SDS lysis buer. NhEGFR cells expressing HA-tagged c-cbl (C) or v-cbl (V) were cultured in DMEM/0.5% FCS for 24 h then stimulated with EGF for 2 min at 378C. Cell lysates were prepared in TBS/ 1% Triton X-100 without SDS (7) demonstration that the corresponding G306E mutation abolishes v-cbl binding to the EGFR (Figures 2 and 3 ) led us to investigate whether this mutation might also abrogate v-cbl transformation. To test this possibility NIH3T3 ®broblasts were infected with retroviruses overexpressing HA-tagged c-cbl, v-cbl and G306E-vcbl and Figure 6a shows that all three proteins were expressed at comparable levels. These ®broblasts are shown in Figure 6b and in agreement with our previous ®ndings (Blake et al., 1993) , overexpression of c-cbl did not induce morphological changes whereas cells overexpressing v-cbl grew in distinct foci and exhibited a refractile appearance characteristic of cellular transformation. More importantly cells overexpressing the G306E-v-cbl mutant showed no signs of transformation and were morphologically indistinguishable from uninfected NIH3T3 ®broblasts or NIH3T3 ®broblasts overexpressing c-cbl (Figure 6b ). The ability of the G306E mutation to ablate v-cbl transformation was further con®rmed by a soft agarose colony assay (Figure 6c ) in which NIH3T3 ®broblasts overexpressing v-cbl were able to form colonies whereas cells expressing either c-cbl or the G306E-v-cbl mutant failed to exhibit anchorage-independent growth.
Discussion
Mutations within cbl's proline-rich region perturb receptor binding but not phosphorylation
Since cbl does not contain a recognizable SH2 or PTB domain the obvious mechanism of cbl's recruitment to the EGF receptor would be predicted to involve an SH3/SH2 adaptor protein. Cbl possesses many potential SH3 binding sites in its 200 amino acid proline-rich domain including a known Grb2 binding site of PPVPPR (amino acids 494 ± 499). Indeed numerous studies have demonstrated constitutive interaction between cbl and Grb2 in vivo Fukazawa et al., 1995; Odai et al., 1995; Wang et al., 1996; Panchamoorthy et al., 1996; Buday et al., 1996) , and ®lter binding studies showed this association to be mediated by sequences in the proline-rich domain (Bowtell and Langdon, 1995) .
Findings shown in Figure 1 revealed that three proline-domain deletion mutants markedly reduced cbl's ability to associate with the EGFR. This clearly demonstrates the importance of this region in mediating the recruitment of c-cbl to the activated receptor. The fact that all three mutants had marked eects raises the possibility that multiple adaptor binding sites are required for a stable interaction. The results also showed an important role for six consecutive proline residues in cbl since their deletion alone had an eect that was at least equivalent to the two larger proline-domain deletions. Indeed the dramatic reduction in receptor binding may principally be due to the lack of the PPVPPR sequence in the D472/540 mutation and the loss of the six proline residues (located at amino acids 543 ± 549) in the D543/ 645 mutation. In contrast to the eect seen on receptor-binding we found that the proline-domain deletions did not perturb EGF-induced tyrosine phosphorylation of cbl. Thus a strong receptor association is not required for cbl phosphorylation and raises the possibility that cbl may be a substrate of src family kinases which are activated following EGF stimulation (Roche et al., 1995) .
v-cbl recruitment to the EGF receptor is only revealed by a truncation that deletes the Ring ®nger
In view of the dramatic eect of the proline-domain deletions in inhibiting receptor recruitment (Figure 1) , it was surprising to ®nd that the v-cbl protein has the ability to bind to the EGFR (Figures 2 and 3) . Thus the large C-terminal truncation that generated v-cbl and activates its oncogenic potential also reveals an ability to form an association with the EGFR. Importantly it appears that this interaction is not used by c-cbl for recruitment to the receptor as this mechanism is not evident in the proline-domain deletions or in the C-terminally truncated form of cbl that retains 480 N-terminal amino acids (Figures 1 and  3) . These results indicate that receptor binding by v-cbl is only revealed following the deletion of sequences which encompass the Ring ®nger domain between amino acids 480 and 357. These ®ndings are reminiscent of those from a study that identi®ed the extent of C-terminal truncation necessary to convert cbl to an oncogenic protein (Andoniou et al., 1994) . This study found that the 480 amino acid construct was not transforming, and additional truncations revealed that the critical event to activate cbl was the removal of amino acids between 366 ± 382. This region is localized at the N-terminus of the Ring ®nger and is deleted from an oncogenic form of cbl in the 70Z/3 pre-B cell lymphoma (Andoniou et al., 1994) . Interestingly the oncogenic 70Z-cbl protein shows greatly enhanced binding to the activated receptor compared to c-cbl (Bowtell and Langdon, 1995) . In view of the ®ndings with v-cbl it is possible that this enhanced binding could be due to an ability of the 70Z-cbl protein to utilize both regions of cbl for recruitment to the EGF receptor.
The mechanism that unveils the v-cbl binding domain, and enhances 70Z-cbl receptor binding, is not known. It is possible that the Ring ®nger mutation causes a conformational change which exposes a binding domain which is normally masked prior to growth factor stimulation, and that this domain is only utilized following c-cbl recruitment to the receptor. Determining whether this region can directly aect the activity of the EGF receptor, and other membrane receptor complexes, will greatly aid the understanding of cbl's role as regulator of cell growth.
v-cbl binding is direct and involves receptor phosphorylation
To analyse the mechanism of interaction between v-cbl and the EGFR we tested whether this binding is dependent on receptor activation and also whether an intermediate protein is required. Results from in vivo and in vitro binding studies (Figures 3 and 4a respectively) clearly demonstrate a dependence on receptor activation and show that this interaction involves direct binding of v-cbl to the receptor. To assess whether phosphorylation is the key activation event to mediate this association ®lter binding studies were carried out on EGFR immunoprecipitates in the absence of a tyrosine phosphatase inhibitor (Figure 4b ). Under these conditions v-cbl binding to the receptor was not detected, and this correlated with a marked decrease in receptor tyrosine phosphorylation. This result suggests that vcbl binds to the EGFR via a novel PTB domain, however additional studies are necessary to characterize this interaction and the involvement of other phosphorylated residues cannot be discounted.
Interestingly, direct EGFR binding in vitro was previously demonstrated by Galisteo et al. (1995) using a GST-fusion encompassing the N-terminal 486 amino acids of c-cbl. However we show here that the 480 amino acid c-cbl mutant does not utilize this domain in vivo (Figure 3) . The reason for this apparent dierence is not known but could be due to the bacterial origin of the 486-cbl GST-fusion protein and therefore its lack of tyrosine phosphorylation. Indeed, the 480-cbl mutant undergoes tyrosine phosphorylation upon stimulation and this may contribute to a conformational change which masks the amino-terminal receptor binding domain in vivo (Figure 3 ). Thus while our ®ndings are consistent with those of Galisteo et al. (1995) in identifying an amino-terminal domain capable of interacting directly with the EGFR in an activation-dependent manner, our studies clearly demonstrate that, in vivo, this domain is only revealed following a truncation to v-cbl which deletes the Ring ®nger domain (Figure 3) .
The deduced amino acid sequence of v-cbl does not show any similarities to either the Shc or IRS-1 PTB domains (Kavanaugh and Williams, 1994; Blaikie et al., 1994; van der Geer et al., 1995; Wolf et al., 1995) which suggests v-cbl recognizes a novel binding motif. Since this region of cbl has been highly conserved through evolution, and c-cbl is an integral component of many growth factor and antigen receptor complexes, it is likely that this motif will be identi®ed in a wide range of signalling proteins.
A loss-of-function mutation from sli-1 ablates v-cbl transformation and EGF receptor binding Genetic analyses in C. elegans identi®ed the cbl homologue, sli-1, as a negative regulator of the EGF signalling pathway and indicated that this eect occurs at the level of the receptor Yoon et al., 1995) . The demonstration of an association between v-cbl and the EGFR in fibroblasts provides the initial biochemical evidence to explain the latter prediction. Sli-1 was identi®ed through a genetic screen in nematodes that display a vulvaless phenotype due to reduction-of-function mutations in the Let-23 receptor tyrosine kinase . However a G315E substitution to sli-1 will suppress the eect of the reduction-of-function mutations and fully restore vulval development (Yoon et al., 1995) . Thus the genetic analysis in C. elegans predicts that wild type sli-1 suppresses signals from the mutant receptor and that this suppression is removed by the G315E mutation in sli-1. Findings presented in this study utilizing the corresponding mutation in v-cbl and c-cbl (i.e. G306E) have revealed the importance of this region in (i) mediating v-cbl binding to the EGFR, (ii) being essential for v-cbl transformation and (iii) enhancing c-cbl phosphorylation and receptor binding.
The eect of the G306E mutation in reducing c-cbl binding to the EGFR (Figure 2 ) suggests that although this region is not used by c-cbl for recruitment to the receptor it is involved in maintaining a stable interaction. This ®nding, and v-cbl binding to the receptor, indicates that c-cbl and sli-1 possess a highly conserved and novel EGFR/Let-23 binding domain. Furthermore these results help to explain the profound eect of the G315E mutation on the sli-1 and how it could perturb its interaction with the Let-23 (Yoon et al., 1995) . The reduced phosphorylation observed in G306E-c-cbl (Figure 2 ) also suggests that this domain may encompass an important kinase substrate recognition site that is lost by amino acid substitution. Interestingly G306 is positioned at 71 to tyrosine 307 (and tyrosine 316 in sli-1) which may represent a prominent site of phosphorylation. The eect of the G306E substitution on c-cbl phosphorylation and receptor binding was found to be very similar to that seen with two aminoterminal deletion mutants (compare lanes 3 and 4 in Figure 1 with lane 3 in Figure 2 ). This region may therefore de®ne a domain of approximately 90 amino acids that has 68% identity between cbl and sli-1.
Results with the G306E substitution in v-cbl provide conclusive evidence for the role of this region in mediating a phosphorylation-dependent association with the EGFR since the mutation abolishes v-cbl's ability to bind to the activated receptor (Figures 2 and  3) . The G306E substitution in v-cbl also ablates its ability to transform NIH3T3 ®broblasts ( Figure 6 ). Thus an intriguing correlation exists between EGFR binding and transformation which indicates this region may represent a regulatory domain that aects the activity of protein tyrosine kinases. This is particularly suggestive in view of cbl's widespread involvement in signal transduction pathways mediated by protein tyrosine kinases. That this is likely to be a general phenomenon is further evidenced by a report which has just emerged demonstrating direct binding by v-cbl to the Zap-70 tyrosine kinase following T cell activation (Lupher et al., 1996) . The v-cbl/Zap-70 interaction can be competitively dissociated by phosphotyrosine peptides and, like the v-cbl/EGFR interaction, is completely abolished by introduction of the G306E mutation (Lupher et al., 1996) .
The correlation between v-cbl transformation and receptor binding has also provided the initial clue as to how such a markedly truncated protein can elicit a biological eect. If the prediction from genetic studies in C. elegans is correct, i.e. that sli-1 and cbl proteins are negative regulators of receptor protein tyrosine kinases, then it is possible that v-cbl may exert its eect by functioning as a dominant negative protein that competes with c-cbl for a binding motif present in a wide range of protein tyrosine kinases. Our ongoing studies will therefore focus on de®ning this binding motif and determining whether c-cbl functions as a negative regulator via a direct interaction with protein tyrosine kinases.
Materials and methods
Cell lines and viruses
NIH3T3 and BALB3T3 ®broblast cell lines were cultured in DMEM supplemented with 10% fetal calf serum (FCS) and 2 mM L-glutamine. NhEGFR is a stable cell line derived from NIH3T3 ®broblasts established by electroporation with a pREP4 vector (Invitrogen) encoding the human EGFR cDNA (gift from Margaret Hibbs, Ludwig Institute for Cancer Research) and selected in 400 mg/ml hygromycin (Calbiochem).
Antibodies
Polyclonal rabbit anti-HA antibodies used for immunoprecipitation of HA-tagged cbl proteins have been described previously (Bowtell and Langdon, 1995) . For immunoblotting, the mouse monoclonal anti-phosphotyrosine (4G10) and the sheep anti-human EGFR antibodies were purchased from UBI, and the mouse monoclonal anti-HA antibody (12CA5) from BaBCO. The mouse monoclonal anti-GST antibody (sc-138) was purchased from Santa Cruz.
Construction and expression of mutants
Construction of the cbl deletion mutants has been described previously (Andoniou et al., 1996) . The D6Pro mutation (deleting sequences encoding amino acids 543 ± 548) and glycine to glutamic acid substitution (G306E) were introduced into c-and v-cbl by site-directed mutagenesis using the pAlter plasmid (Promega). Sitedirected mutagenesis was also used to introduce stop codons at amino acids 1029 and 964 of the human EGFR to generate the 1028 and 963 EGFR C-terminal truncation mutants. All mutants were con®rmed by DNA sequencing (Sequenase, USB). Cbl constructs were epitope-tagged with a single copy of the sequence encoding a nine amino acid peptide from the in¯uenza virus hemagglutinin (HA) protein (Wilson et al., 1984) and subcloned into the pJZenNeo retroviral vector (Johnson et al., 1989) while wild type and EGFR mutants were subcloned into the pBabe retroviral vector. Constructs were electroporated into c2 packaging cells to generate virus particles for infection of NIH3T3, NhEGFR or BALB3T3 ®broblasts and selected in 400 mg/ml geneticin (G418, Gibco BRL) or 2 mg/ml puromycin (Sigma) as previously described (Blake et al., 1993) .
Retroviral transformation of NIH3T3 ®broblasts
Infected NIH3T3 ®broblasts were selected in 400 mg/ml geneticin (Gibco BRL) and tested for transformation by anchorage-independent growth in 0.33% soft agarose overlaid on 0.5% soft agarose (DMEM containing 10% FCS, 0.225% NaHCO 3 and 0.33% or 0.5% low melting point agarose respectively). Macroscopic colonies were counted 20 days after plating 10 3 cells in soft agarose.
EGF stimulation
Cells were grown to 90% con¯uency and made quiescent by culturing in DMEM containing 0.5% or 0.25% FCS for 24 h prior to EGF stimulation. Cells were either left quiescent or stimulated with 50 ng/ml EGF for 2 min at 378C and lysates prepared immediately. For serum stimulation, quiescent cells were incubated with DMEM containing 25% FCS for 5 min at 378C before lysis.
Immunoprecipitations and immunoblotting
Cells (5 ± 10610 6 ) were washed in Tris-buered saline (TBS; 150 mM NaCl, 20 mM Tris pH 7.4) and then lysed in 1 ml of ice-cold TBS containing 1% Triton X-100, 1 mM EDTA, 1 mM sodium orthovanadate (Na 3 VO 4 ), 10 mM NaF, 10 mg/ml aprotinin and 1 mg/ml each of chymostatin, leupeptin, antipain and pepstatin. For the ®lter binding assay, some immunoprecipitations were performed as above but without the tyrosine phosphatase speci®c inhibitor, Na 3 VO 4 . Cell debris and nuclei were removed by centrifugation at 6 000 r.p.m. in a microfuge for 5 min at 48C. Cleared lysates were incubated with rabbit anti-HA antibodies for 3 h at 48C followed by incubation for 2 h with protein-A Sepharose (Pharmacia). Immune complexes were washed 5 times in lysis buer before suspension and boiling in Laemmli sample buer. For Ni 2+ -agarose precipitation of cbl proteins, cells were lysed in ice-cold TBS containing 1% Triton X-100, 5 mM imidazole, 10% glycerol, 1 mM sodium orthovanadate, 10 mg/ml aprotinin and 1 mg/ml each of chymostatin, leupeptin, antipain and pepstatin. Cleared lysates were incubated with 40 ml Ni 2+ -agarose beads (Qiagen) for 2 h at 48C. The beads were washed four times with TBS containing 5 mM imidazole and 1 mM sodium orthovanadate before suspension and boiling in Laemmli sample buer. Ni 2+ -agarose bound proteins or immune complexes were electrophoretically separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Bound proteins were detected by immunoblotting with anti-HA, anti-phosphotyrosine or anti-EGFR antibodies and visualized using horse-radish peroxidase conjugated antibodies and ECL reagents (Amersham) as previously described (Andoniou et al., 1994) .
GST-v-cbl ®lter binding assay
Construction of the GST-v-cbl fusion which encodes the entire v-cbl sequence fused downstream of glutathione-Stransferase has been described previously . GST-v-cbl fusion proteins were inducibly expressed in E. coli and puri®ed on glutathione sepharose beads following the method of Smith and Johnson (1988) . Membranes were blocked for 1 h in 5% non-fat milk, 0.1% Tween-20, 20 mM Tris pH 7.4, 150 mM NaCl and 1 mM Na 3 VO 4 then probed with approximately 3 mg/ml GST-v-cbl for 1.5 h in blocking solution. After four 5 min washes, bound proteins were detected by immunoblotting with anti-GST antibodies and ECL reagents as previously described (Andoniou et al., 1994) . In the case of EGFR samples immunoprecipitated in the absence of the tyrosine phosphatase inhibitor, Na 3 VO 4 , the membrane was blocked and probed as above but omitting Na 3 VO 4 from the blocking and wash buers.
